Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) have earned an average rating of “Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in […]
Pliant Therapeutics (NASDAQ:PLRX – Get Rating) had its price target lifted by Cantor Fitzgerald from $52.00 to $63.00 in a report released on Monday, The Fly reports. A number of other research analysts have also recently commented on PLRX. JPMorgan Chase & Co. reduced their target price on shares of Pliant Therapeutics from $51.00 to […]
Needham & Company LLC reiterated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report released on Thursday, Benzinga reports. Needham & Company LLC currently has a $45.00 price target on the stock. PLRX has been the subject of several other research reports. HC Wainwright reaffirmed a buy rating […]
Robert W. Baird assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $44.00 price target on the stock. Other equities research analysts also recently issued reports about the company. Citigroup cut their […]